12 Best Global Stocks to Buy According to Hedge Funds

Page 4 of 12

9. AstraZeneca PLC (NASDAQ:AZN)

Number of Hedge Fund Holders: 55

AstraZeneca PLC (NASDAQ:AZN) manufactures and sells pharmaceutical and medical products. For the fiscal year 2024, total revenue increased by 21% to $54,073 million, driven by a 19% rise in product sales, continued growth in partnered medicines (alliance revenue), and the achievement of sales-based milestones (collaboration revenue). In February, the company received a recommendation for approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its drug Imfinzi (durvalumab) as a treatment for adults with limited-stage small cell lung cancer (LS-SCLC). In addition to improving OS, Imfinzi also showed a 24% reduction in the risk of disease progression or death, extending progression-free survival (PFS) to a median of 16.6 months, compared to 9.2 months for placebo.

Page 4 of 12